Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients
Jonathan W. Riess(University of California Davis Medical Center), Heather A. Wakelee(Palo Alto Institute), Edgar G. Engleman(Stanford Medicine), Joel W. Neal(Stanford Medicine), Nupur Bhattacharya(Zero to Three), Kim Blenman(Medical University of South Carolina), Gloria L. Hwang(Stanford University), Philippe Pultar(Department of Pharmaceuticals), Rajesh Malik(Agennix (United States)), Peter P. Lee(City Of Hope National Medical Center), Melanie San-Pedro Salcedo(Stanford University)
Cited by 4
Related Papers
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
|Annual Review of Pathology Mechanisms of Disease|2020|2.2k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
|Nature Medicine|1999|1.1k